Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

par pharmaceutical companies, inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl=ca in mg/dl + 0.8 (4.0 g/dl - patient albumin [g/dl]). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see adverse reactions (6.2) ].

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

jhp pharmaceuticals, llc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3.0 mmol/l] using the formula: cca in mg/dl=ca in mg/dl + 0.8 (4.0 g/dl - patient albumin (g/dl)). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other nontumor-related conditions have not been established. hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see adverse reactions (6.2) ]. pregnancy category d [see warnings and precautions (5.9)] there are no adequate a

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

kent pharma (uk) ltd - magnesium trisilicate; aluminium hydroxide dried - oral tablet - 250mg ; 120mg

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

dalkeith laboratories ltd - magnesium trisilicate; aluminium hydroxide dried - oral tablet - 250mg ; 120mg

Malta - anglų - Medicines Authority

bayer limited 1st floor the grange offices the grange brewery road stillorgan co. dublin, a94 h2k7 , ireland - calcium carbonate, magnesium carbonate, heavy, alginic acid - chewable tablet - calcium carbonate 625 mg magnesium carbonate, heavy 73.5 mg alginic acid 150 mg - drugs for acid related disorders

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

gambro renal products - calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb, chloride ion - unii:q32zn48698), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838, chloride ion - unii:q32zn48698), dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok), lactic acid (unii: 33x04xa5at) (lactic acid - unii:33x04xa5at), sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37, chloride ion - unii:q32zn48698), sodium bicarbonate (unii: 8mdf5v39qo) (sodium cation - - calcium chloride 0.139 g in 1 l - there is no known contraindication to the use of prismasol solution. pregnancy category c. prismasol solution is a replacement solution of electrolytes, bicarbonate and dextrose and is pharmacologically inactive. animal reproduction studies have not been conducted with prismasol solution. while there are no adequate and well controlled studies in pregnant women, appropriate administration of prismasol solution with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to cause fetal harm, or affect reproductive capacity. maintenance of normal acid-base balance is important for fetal well being. prismasol solution is a replacement solution of electrolytes, bicarbonate and dextrose and is pharmacologically inactive. the components of prismasol solution are excreted in human milk. appropriate administration of prismasol solution with monitoring of fluid, electrolyte, acid-base and glucose balance, is not expected to harm a nursing infant. safety and effectiveness have been established

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

par pharmaceutical companies, inc. - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 5 mg in 100 ml - zoledronic acid injection is indicated for treatment of paget's disease of bone in men and women. treatment is indicated in patients with paget’s disease of bone with elevations in serum alkaline phosphatase of two times or higher than the upper limit of the age-specific normal reference range, or those who are symptomatic, or those at risk for complications from their disease [see clinical studies (14.5) ]. zoledronic acid injection is contraindicated in patients with the following conditions: - hypocalcemia [see warnings and precautions (5.2) ] - creatinine clearance less than 35 ml/min and in those with evidence of acute renal impairment due to an increased risk of renal failure [see warnings and precautions (5.3) ]. - known hypersensitivity to zoledronic acid or any components of zoledronic acid injection. hypersensitivity reactions including urticaria, angioedema, and anaphylactic reaction/shock have been reported [see post-marketing experience (6.2) ]. pregnancy category d [see warnings and precautions

Australija - anglų - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ibandronate sodium, quantity: 56.25 mg (equivalent: ibandronic acid, qty 50 mg) - tablet, film coated - excipient ingredients: povidone; crospovidone; stearic acid; hypromellose; colloidal anhydrous silica; purified talc; macrogol 6000; lactose monohydrate; microcrystalline cellulose; titanium dioxide - the treatment of metastatic bone disease in patients with breast cancer.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - ibandronate sodium, quantity: 1.125 mg/ml (equivalent: ibandronic acid, qty 1 mg/ml) - injection, concentrated - excipient ingredients: sodium chloride; glacial acetic acid; sodium acetate; water for injections - indicated for the treatment of: tumor-induced hypercalcaemia with or without metastases. metastatic bone disease in patients with breast cancer.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

mylan institutional llc - zoledronic acid (unii: 6xc1pad3kf) (zoledronic acid anhydrous - unii:70hz18ph24) - zoledronic acid anhydrous 4 mg in 5 ml - zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy defined as an albumin-corrected calcium (cca) of greater than or equal to 12 mg/dl [3 mmol/l] using the formula: cca in mg/dl = ca in mg/dl + 0.8 (4 g/dl - patient albumin [g/dl]). zoledronic acid injection is indicated for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. prostate cancer should have progressed after treatment with at least one hormonal therapy. limitations of use the safety and efficacy of zoledronic acid injection in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions have not been established. hypersensitivity to zoledronic acid or any components of zoledronic acid injection hypersensitivity reactions including rare cases of urticaria and angioedema, and very rare cases of anaphylactic reaction/shock have been reported [see adverse r